The Goldman Sachs Group Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

Syndax Pharmaceuticals (NASDAQ:SNDXFree Report) had its price objective upped by The Goldman Sachs Group from $30.00 to $33.00 in a research report sent to investors on Thursday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Citigroup increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Bank of America increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Stifel Nicolaus lifted their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, October 14th. JPMorgan Chase & Co. dropped their target price on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, UBS Group initiated coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price for the company. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.82.

Check Out Our Latest Stock Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Stock Up 1.3 %

Syndax Pharmaceuticals stock opened at $21.81 on Thursday. The business has a 50 day moving average price of $19.11 and a two-hundred day moving average price of $20.33. Syndax Pharmaceuticals has a 12 month low of $13.14 and a 12 month high of $25.34. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -6.01 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. On average, analysts expect that Syndax Pharmaceuticals will post -3.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Syndax Pharmaceuticals by 13.6% in the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after buying an additional 591,631 shares during the last quarter. Sofinnova Investments Inc. increased its position in Syndax Pharmaceuticals by 33.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock valued at $44,215,000 after acquiring an additional 545,129 shares in the last quarter. First Turn Management LLC raised its stake in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock worth $22,853,000 after acquiring an additional 546,776 shares during the last quarter. StemPoint Capital LP grew its stake in shares of Syndax Pharmaceuticals by 0.6% during the first quarter. StemPoint Capital LP now owns 1,100,988 shares of the company’s stock valued at $26,204,000 after purchasing an additional 6,494 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Syndax Pharmaceuticals by 56.3% in the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock valued at $21,875,000 after purchasing an additional 383,634 shares in the last quarter.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Read More

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.